Stage IIIA Skin Melanoma Completed Phase 1 Trials for DB00877 (Sirolimus)

IndicationStatusPhase
DBCOND0029533 (Stage IIIA Skin Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01522820Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsTreatment